Southlake, Texas, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of Artificial Intelligence (AI), today announced that Andrew Simpson, Chief Executive Officer of HeartSciences, has been invited to appear as a featured guest on the Big Biz Show, an Emmy Award-winning nationally syndicated radio and TV program.

The show will air today, February 7, 2023, at 11:45 a.m. Pacific Time / 2:45 p.m. Eastern Time. Check local listings for times in your area. The show will air on cable TV on Fox Business, NBCUniversal, and Time Warner Cable, and streaming services, including Roku, Apple TV, fire TV, as well as on radio via The Biz Talk Radio Network, Armed Forces Radio and iHeart Media in 175 countries. Podcasts available on iHeart Radio, Apple Podcasts, Speaker.com and TuneIn. Also available to subscribers of biztv.com or ytaclub.com. Additionally, the show will be available on the Investor Relations section of the Company’s website 48 hours after it airs.

Mr. Simpson will discuss the benefits of its MyoVista® device including how it utilizes artificial intelligence to detect heart disease early in at-risk patients and how the use of the MyoVista® in a front-line physician setting is designed to save lives.

Andrew Simpson, Chief Executive Officer of HeartSciences, commented, “Millions of ECGs are performed every week, yet they have significant limitations in identifying many forms of heart disease. HeartSciences is at the leading edge of changing what’s possible with an ECG by applying AI to make an ECG a far more valuable screening tool for heart disease detection in order to save lives. I look forward to speaking more in-depth about HeartSciences and our MyoVista® device.”

About HeartSciences

Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG’s clinical usefulness. Millions of ECGs are performed every week and the Company’s objective is to improve healthcare by making an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences’ first product candidate for FDA clearance, the MyoVista® wavECG, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista® also provides conventional ECG information in the same test. The business model, which involves the use of the MyoVista® device and consumables for each test, is expected to be “razor-razorblade” as the electrodes used with the MyoVista® are proprietary to HeartSciences, and new electrodes are required for every test performed.

For more information, please visit: https://www.heartsciences.com. Twitter: @HeartSciences

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences’ beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences’ filings with the U.S. Securities and Exchange Commission at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For investor and media inquiries, please contact:
Investor Relations:
Crescendo Communications, LLC
Phone: (212) 671-1021
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Company:
Gene Gephart
Phone: +1-737-414-9213 (US)
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.